Literature DB >> 7656229

In vivo growth inhibitory and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma.

P U Devi1, A C Sharada, F E Solomon.   

Abstract

Adult Swiss albino mice were inoculated intraperitoneally (i.p.) with 10 (6) Ehrlich ascites carcinoma cells. Twenty-four hours later they were given an i.p. injection of 10-60 mg/kg of withaferin A (WA), isolated from the roots of Withania somnifera. The tumor growth and tumor free animal survival were studied for up to 120 days. In another experiment 30 mg/kg WA was injected i.p. to mice at 1, 3 or 5 days after tumor cell injection with or without acute abdominal exposure to 7.5 Gy gamma radiation and the tumor growth and 120-day survival were studied. WA inhibited tumor growth and increased tumor free survival in a dose-dependent manner. The drug ED50 for 120-day survival was approximately 30 mg/kg body wt. Drug treatment before irradiation synergistically increased 120-day even in advanced tumors. A dose of 30 mg/kg seems to be optimum for combination with radiation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7656229     DOI: 10.1016/0304-3835(95)03892-z

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

1.  Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells.

Authors:  Joomin Lee; Eun-Ryeong Hahm; Shivendra V Singh
Journal:  Carcinogenesis       Date:  2010-08-19       Impact factor: 4.944

2.  Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo.

Authors:  Silvia D Stan; Eun-Ryeong Hahm; Renaud Warin; Shivendra V Singh
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 3.  Withaferin A and its potential role in glioblastoma (GBM).

Authors:  Jasdeep Dhami; Edwin Chang; Sanjiv S Gambhir
Journal:  J Neurooncol       Date:  2016-11-11       Impact factor: 4.130

4.  Withaferin a suppresses estrogen receptor-α expression in human breast cancer cells.

Authors:  Eun-Ryeong Hahm; Joomin Lee; Yi Huang; Shivendra V Singh
Journal:  Mol Carcinog       Date:  2011-03-22       Impact factor: 4.784

Review 5.  Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone.

Authors:  Avani R Vyas; Shivendra V Singh
Journal:  AAPS J       Date:  2013-09-18       Impact factor: 4.009

6.  Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells.

Authors:  Silvia D Stan; Yan Zeng; Shivendra V Singh
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

7.  Differential activities of the two closely related withanolides, Withaferin A and Withanone: bioinformatics and experimental evidences.

Authors:  Kirti Vaishnavi; Nishant Saxena; Navjot Shah; Rumani Singh; Kavyashree Manjunath; M Uthayakumar; Shankar P Kanaujia; Sunil C Kaul; Kanagaraj Sekar; Renu Wadhwa
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

8.  Withaferin A induces proteasome inhibition, endoplasmic reticulum stress, the heat shock response and acquisition of thermotolerance.

Authors:  Saad Khan; Ashley W Rammeloo; John J Heikkila
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

9.  Evaluation of the bioavailability of major withanolides of Withania somnifera using an in vitro absorption model system.

Authors:  Santosh T Devkar; Amit D Kandhare; Brian D Sloley; Suresh D Jagtap; James Lin; Yun K Tam; Surendra S Katyare; Subhash L Bodhankar; Mahabaleshwar V Hegde
Journal:  J Adv Pharm Technol Res       Date:  2015 Oct-Dec

Review 10.  Withaferin-A--A Natural Anticancer Agent with Pleitropic Mechanisms of Action.

Authors:  In-Chul Lee; Bu Young Choi
Journal:  Int J Mol Sci       Date:  2016-03-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.